Premium
Genetic differences between paediatric and adult Burkitt lymphomas
Author(s) -
Havelange Violaine,
Pepermans Xavier,
Ameye Geneviève,
Théate Ivan,
CalletBauchu Evelyne,
Barin Carole,
Penther Dominique,
Lippert Eric,
Michaux Lucienne,
Mugneret Francine,
Dastugue Nicole,
Raphaël Martine,
Vikkula Miikka,
Poirel Hélène A.
Publication year - 2016
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13925
Subject(s) - cdkn2a , loss of heterozygosity , exon , medicine , copy number variation , gene deletion , oncology , genetics , biology , cancer research , gene , allele , genome , mutant
Summary Dysregulation of MYC is the genetic hallmark of Burkitt lymphoma ( BL ) but it is encountered in other aggressive mature B‐cell lymphomas. MYC dysregulation needs other cooperating events for BL development. We aimed to characterize these events and assess the differences between adult and paediatric BL s that may explain the different outcomes in these two populations. We analysed patterns of genetic aberrations in a series of 24 BLs: 11 adults and 13 children. We looked for genomic imbalances (copy number variations), copy‐neutral loss of heterozygosity ( CN ‐ LOH ) and mutations in TP53 , CDKN2A , ID3 (exon 1), TCF3 (exon17) and CCND3 (exon 6). Young patients displayed more frequent 13q31.3q32.1 amplification, 7q32q36 gain and 5q23.3 CN‐ LOH , while 17p13 and 18q21.3 CN ‐ LOH were only detected in adult BL s. ID 3 mutations were present in all adult samples, but only in 42% of childhood cases. CCND 3 and ID 3 double‐hit mutations, as well as 18q21 CN ‐ LOH , seemed to be associated with poorer outcome. For the first time, we report different genetic anomalies between adult and paediatric BL s, suggesting age‐related heterogeneity in Burkitt lymphomagenesis. This may explain the poorer prognosis of adult BL s. Additional studies are needed to confirm these results in the setting of clinical trials.